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        The immune system defends the host by exert-
ing a wide array of responses to invading patho-
gens and other noxious antigens. Upon invasion, 
these foreign organisms and substances induce 
nonspecifi  c infl  ammation. Concomitantly, they 
are ingested by APCs such as DCs and macro-
phages. APCs process them while they migrate 
toward draining LNs, and present processed 
antigens to naive T cells in the LNs. Engagement 
of the antigen complex by T cell receptor triggers 
clonal expansion and diff  erentiation of T cells, 
which critically determines the outcome of im-
mune responses (  1, 2  ). CD4  +   T cells play a central 
role in orchestrating immune responses through 
their capacity to provide help to other cells, and 
can be categorized into Th1 cells characterized by 
secretion of IFN-     , Th2 cells characterized by 
secretion of IL-4, IL-5, IL-6, and IL-13, and 
recently identifi  ed Th17 cells characterized by 
secretion of IL-17A. Similarly, CD8  +   T cells 
undergo diff  erentiation into two subsets of cyto-
toxic T cells, Tc1 and Tc2 cells. In immune re-
sponses, Th1 cells are responsible for cell-mediated 
infl  ammatory reactions, such as delayed type 
hypersensitivity reaction, and are critical for eradi-
cation of intracellular pathogens, whereas Th2 
cells are involved in optimal antibody   production, 
particularly IgE and IgG1 subtypes, and elicit 
allergic/humoral immune response against extra-
cellular pathogens, and Th17 cells mediate host im-
mune response against extracellular bacteria, some 
fungi, and other microbes, which are probably 
not well covered by Th1 or Th2 immunity (  3  ). 
  During antigen presentation, APCs produce 
a variety of cytokines and other substances, and 
the composition of cytokines to which naive 
T cells are exposed determines the fate of T cell 
diff  erentiation (  4, 5  ). IL-12, IL-4, and trans-
forming growth factor-      with IL-6 are key de-
terminants of T cell diff  erentiation into Th1, 
Th2, and Th17, respectively. Although these cy-
tokine-directed pathways make basic frameworks 
for T cell diff  erentiation, and the signal transduc-
tion and transcription factors involved therein 
have been determined, polarization of T cell re-
sponse in vivo may be infl  uenced by other non-
cytokine substances in local milieu, one candidate 
being prostanoids. 
  Prostanoids, including prostaglandin (PG) D  2  , 
PGE  2  , PGF  2      , PGI  2  , and thromboxane A  2  , are 
metabolites of arachidonic acid produced by the 
sequential actions of cyclooxygenase (COX) and 
respective synthases (  6  ). They are formed in re-
sponse to various, often noxious, stimuli, and 
they regulate a broad range of physiological and 
pathological processes. Among prostanoids, PGE  2   
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reaction in vivo. Thus, this study revealed an important role of 
EP1 on T cells in Th1 response and raises an intriguing possibil-
ity that PGE  2   acts on diff  erent types of EP and can skew T cell 
diff  erentiation into either Th1 or Th2 direction via EP1 or 
EP2/EP4, respectively, in a context-dependent manner. 
      RESULTS   
    EP1 signaling works in the sensitization phase to regulate 
CHS response 
  To investigate the role of EP1 during CHS, we sensitized 
WT mice and EP1    −  /  −    mice by painting DNFB on shaved ab-
domen, and we challenged the ear 5 d later by epicutaneous 
is produced most abundantly in various phases of immune 
responses, and its actions on T cell development have been 
studied for many years. It was already known in the 1980s 
that PGE  2   is produced by APCs, inhibits production of IL-2 
and IFN-     , and suppresses proliferation of murine, as well as 
human, T cells in vitro (  7, 8  ). Betz and Fox (  9  ) examined the 
eff  ect of PGE  2   on cytokine production from Th1, Th2, and 
Th0 clones, and found that PGE  2   inhibited production of IL-2 
and IFN-     , which are two Th1 cytokines, whereas it spared 
production of the Th2 cytokines IL-4 and -5. This diff  erential 
action of PGE  2   on Th1 and Th2 cells has been confi  rmed by 
many studies (  10  –  14  ). Because the best known action of PGE  2   
is elevation of intracellular cAMP, and cAMP exerts similar 
Th1-selective suppression (  15, 16  ), most, if not all, studies have 
assigned PGE  2   as a modulator of T cells raising the intracellular 
cAMP level. PGE  2   acts on a rhodopsin-type, G protein  –  cou-
pled receptor to exert its actions. There are four subtypes of 
PGE receptor, termed EP1, EP2, EP3, and EP4, among which 
EP2 and EP4 are coupled to a rise in cAMP. Nataraj et al. (  17  ) 
used T cells obtained from mice defi  cient in each EP subtype 
individually, and examined an immunosuppressive eff  ect of 
PGE  2   in vitro in mixed lymphocyte reaction. They found that 
the immunosuppressive action of PGE  2   was signifi  cantly atten-
uated in T cells obtained either from EP2    −  /  −    or EP4    −  /  −    mice, 
suggesting that both EP2 and EP4 mediate suppression of PGE  2   
on T cells. Kabashima et al. (  18  ) additionally found that the 
EP4-mediated T cell suppression operates in vivo in intestinal 
infl  ammation of mice treated with dextran sodium sulfate. 
  Curiously, the fi  nding by Kabashima et al. (  18  ) is a rare 
example showing in vivo occurrence of the PGE  2  -mediated 
immunosuppression. Treatment of animals with COX inhibitors 
does not necessarily enhance Th1 response. Indeed, T cell sup-
pression by PGE  2   has been shown mostly in experiments using 
in vitro culture systems. One possible explanation for this dis-
crepancy between the in vitro and in vivo fi  ndings is that PGE  2   
elicits not only anti-Th1 actions but also other actions on T cells 
as well. Naive T cells express, in addition to EP2 and EP4, the 
EP1 receptor that couples to a rise in intracellular Ca  2+   concen-
tration, and therefore can exert actions diff  erent from EP2 and 
EP4 in T cells (reference   17   and this study). Because the Th1 
and Th2 paradigm is well established, we focused on the role 
of EP1 on Th1 and Th2 immune response. Contact hypersensi-
tivity (CHS) is a form of delayed-type hypersensitivity, a T cell  –
  mediated immune response to reactive haptens, and it clinically 
manifests as contact dermatitis. Th1 lymphocytes play critical 
roles in CHS, although Th17 lymphocytes also, to some extent, 
contribute to CHS (  19, 20  ). Dinitrofl  uorobenzene (DNFB)-in-
duced CHS is an experimental model of a typical Th1-mediated 
CHS in which IFN-      is a critical mediator (  19, 21  ). We there-
fore used DNFB-induced CHS in this study and examined the 
role of EP1 in T cell-mediated immune responses by using EP1-
defi  cient (EP1    −  /  −   ) mice, as well as an EP1-selective agonist and 
antagonist. We have found that PGE  2   acts on EP1 in naive 
T cells and augments their diff  erentiation to the Th1 subset 
in vitro, and this signaling critically works in the sensitization 
phase and facilitates Th1-mediated delayed hypersensitivity 
  Figure 1.     Impaired CHS responses in EP1    −  /  −    mice. (A) Ear swelling. 
WT mice and EP1   − / −    mice were sensitized with DNFB (Sensitization [+]) or 
vehicle (Sensitization [-]), challenged with DNFB 5 d later, and ear thick-
ness was measured 24 h after the challenge (unpaired Student  ’  s   t   test; 
  n   = 5 mice per group). (B) Histology of DNFB-treated ears. Transverse 
sections of the ear from WT mice and EP1   − / −    mice 24 h after the challenge 
were stained with hematoxylin and eosin. Bar, 100      m. (C) Effect of EP1 
antagonist ONO-8713 on CHS to DNFB. WT mice were administered with 
either vehicle (N) or ONO-8713 all through the experimental period (T), or 
during sensitization (S) or elicitation (E) period, and the ear thickness was 
measured 24 h after challenge (unpaired Student  ’  s   t   test;   n   = 5 mice per 
group). Data are representative of at least three experiments with similar 
results. Data are presented as the mean   ±   the SEM.     JEM VOL. 204, November 26, 2007 
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application of DNFB to elicit CHS response (  22, 23  ). Although 
both WT and EP1    −  /  −    mice developed ear swelling after DNFB 
application, as measured by an increase in ear thickness, the ear 
swelling in EP1    −  /  −    mice was signifi  cantly attenuated compared 
with that found in WT mice (  Fig. 1 A  ).   Histological examina-
tion showed that antigen challenge induced considerable lym-
phocyte infi  ltration and edema in the dermis and spongiosis in 
the epidermis of the ear in sensitized (but not naive) WT mice, 
and that these changes were less apparent in sensitized EP1    −  /  −    
mice than WT mice (  Fig. 1 B  ). To confi  rm these fi  ndings in 
EP1    −  /  −    mice, we next examined the eff  ect of pharmacological 
inhibition of EP1 on the CHS response by administering an 
EP1-selective antagonist ONO-8713 (  24  ) orally at 20 mg/kg/
day to the WT mice. ONO-8713 administered all through 
the experimental period (T) reduced the ear swelling as found 
in EP1    −  /  −    mice (  Fig. 1 C  ). To determine the eff  ective time 
window of EP1 antagonist, we then administered ONO-8713 
selectively either during the sensitization period (S) or during 
the elicitation period (E). Treatment of ONO-8713 during the 
sensitization period, but not during the elicitation period, in-
hibited the ear swelling to the extent comparable to that found 
in EP1    −  /  −    mice or WT mice treated with ONO-8713 all 
through the experimental period (  Fig. 1 C  ). These results sug-
gest that EP1 signaling specifi  cally works in the sensitization 
phase and regulates the DNFB-induced CHS response. 
  Impaired IFN-     production with intact lymphocyte 
proliferation in the draining LNs of EP1    −  /  −    mice 
after DNFB application 
  To examine how the loss of EP1 aff  ected sensitization of CHS 
response, we next analyzed the composition and diff  erentiation 
of cells in draining LNs of EP1    −  /  −    mice before and after sensi-
tization. Under the basal condition, EP1    −  /  −    mice showed no 
apparent abnormality in either the number or composition of 
immune cells, and, upon DNFB sensitization, they exhib-
ited an increase in the total cell number comparable to that 
found in WT mice with a composition similar to that in WT 
mice (  Fig. 2 A  ).   Consistently, when the LN cells were col-
lected from sensitized animals and challenged with dinitroben-
zene sulfonic acid (DNBS) in vitro, [  3  H]thymidine uptake was 
not signifi  cantly diff  erent between the two groups (  Fig. 2 B  ). 
Intriguingly, however, production of IFN-      induced by the 
DNBS challenge was markedly decreased in cells from EP1    −  /  −    
mice as compared with those from WT mice (  Fig. 2 C  ), whereas 
production of IL-4 was not suppressed in the cells from EP1    −  /  −    
mice (  Fig. 2 D  ). Because DNFB-induced CHS is a typical 
Th1-mediated, delayed-type hypersensitivity reaction and 
IFN-      is a critical mediator (  25, 26  ), these results indicate that 
diff  erentiation of naive T cells to the Th1 subset is impaired in 
EP1    −  /  −    mice, and this can be a cause of impaired CHS ob-
served in this genotype of mice. 
  Impaired Th1 differentiation in draining LNs of EP1    −  /  −    mice 
leads to reduced Th1 response in elicitation phase of CHS 
  To verify the aforementioned hypothesis, we next analyzed the 
number of cells expressing T-box-expressed-in-T cells (T-bet), 
  Figure 2.     Impaired development of Th1 subset in CHS to DNFB 
in EP1    −  /  −    mice. (A) Number of CD4  + ,  CD8 + ,  B220 +  , and Thy1.2  +   cells  in 
draining LNs (LNs) before and after antigen application. Cells from in-
guinal and axillary LNs were collected before or 5 d after DNFB applica-
tion, and the number of CD4  + ,  CD8 + ,  B220 +  , and Thy1.2  +   cells  was 
analyzed by fl  ow cytometry (  n   = 5 mice per group). (B) DNBS-induced 
lymphocyte proliferation. Cells were collected from LNs of WT or EP1   − / −   
mice 3 d after DNFB application, and cultured for 3 d with or without 
DNBS. Cell proliferation was measured by [  3 H]thymidine  incorporation 
(  n   = 5 mice per group). (C and D) DNBS-induced cytokine production. 
Cells were isolated from LNs of WT or EP1   − / −    mice 3 d after DNFB appli-
cation, and cultured in the absence or presence of DNBS for 2 d. The 
amount of IFN-      (C) or IL-4 (D) in the culture medium was measured by 
ELISA (unpaired Student  ’  s   t   test;   n   = 5 mice per group). Data are repre-
sentative of at least three experiments with similar results. Data are 
presented as the mean   ±   the SEM.     2868 FACILITATION OF TH1 RESPONSE BY PGE RECEPTOR EP1 | Nagamachi et al.
CHS model are cutaneous DCs, such as Langerhans cells (LCs) 
and dermal DCs (  25  ). After encountering DNFB, cutaneous 
DCs migrate to LNs and undergo maturation during migra-
tion, which includes increased expression of MHC and co-
stimulatory molecules at their cell surface and the production 
of cytokines, one being IL-12, which is a key cytokine for 
Th1 diff  erentiation of CD4  +   T cells (  1, 5  ). Because EP1 is ex-
pressed, albeit weakly, on cutaneous DCs (  23  ), we examined 
whether EP1 is involved in the functions of cutaneous DCs by 
comparing abundance, migration, and maturation of cutane-
ous DCs during CHS between WT and EP1    −  /  −    mice. Consis-
tent with the fi  nding that T cell proliferation, by itself, occurred 
normally in EP1    −  /  −    mice, we did not detect any diff  erence 
which is a key transcription factor for Th1 diff  erentiation (  27  ), 
in draining LNs. Sensitization with DNFB increased the 
number of T-bet  –  expressing cells in both WT and EP1    −  /  −    
mice. However, the number of T-bet  –  expressing cells in 
EP1    −  /  −    mice was signifi  cantly reduced (  Fig. 3 A  ).   Consis-
tently, restimulation of sensitized LN cells with DNBS in-
creased the expression levels of both T-bet and IL-12R     2 
mRNA in WT mice, whereas the DNBS eff  ects on cells 
from EP1    −  /  −    mice was signifi  cantly reduced (unpublished 
data). These results suggest that EP1    −  /  −    mice contain a re-
duced number of CD4  +   T cells primed to induce T-bet 
expression, which leads to attenuation of Th1 response. In-
deed, cervical LNs after DNFB challenge to the ear in the 
elicitation phase showed a signifi  cant decrease in EP1    −  /  −    
mice in the total cell number and the numbers of IFN-       –
  producing cells in the CD8  +   cell population (  Fig. 3, B and C  ). 
This IFN-       –  producing CD8  +   cell population consisted mainly 
of CD3  +   T cells, although CD11c  +   DCs were one source of 
IFN-      in this population (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20070773/DC1). The number of 
IFN-       –  producing cells in the CD4  +   T cell pop  ulation was 
also substantially decreased in EP1    −  /  −    mice (  Fig. 3 C  ). 
  Given that, in addition to Th1 cells, Tc1 cells also function 
as eff  ector cells in CHS (  28  –  30  ), the aforementioned results 
indicate that reduced generation of Th1 and Tc1 cells underlie 
impaired CHS response in EP1    −  /  −    mice. To verify this hypoth-
esis, we isolated and pooled T cells from regional LNs of 
DNFB-sensitized WT or EP1    −  /  −    donors and adoptively trans-
ferred the cells into naive WT recipients. The recipients of 
sensitized EP1    −  /  −    T cells demonstrated suppressed CHS re-
sponses compared with the recipients of sensitized WT T cells 
(  Fig. 4 A  ).   Conversely, when T cells from WT donors were 
transferred into naive EP1    −  /  −    recipients, subsequent challenge 
with DNFB elicited a normal CHS response (  Fig. 4 B  ), indi-
cating that sensitized T cells and not other cells are essential for 
EP1-dependent amplifi  cation of CHS response. 
  To examine the specifi  city of the impairment of immune 
response in EP1    −  /  −    mice, we analyzed the Th2 response in 
EP1    −  /  −    mice by immunizing the mice with OVA, which is 
a typical protein antigen for Th2 response (  31  ). The serum con-
centrations of total IgE and OVA-specifi  c IgE were measured at 
12 d after OVA administration. OVA immunization increased 
the concentrations of total and OVA-specifi  c IgE in WT and 
EP1    −  /  −    mice (Fig. S2, A and B, available at http://www.jem
.org/cgi/content/full/jem.20070773/DC1). Although there 
was no signifi  cant diff  erence, the concentrations in EP1    −  /  −    mice 
tended to be higher than those in WT mice. These results sug-
gest that EP1    −  /  −    mice have impairment specifi  cally in the devel-
opment of Th1 response, but not Th2 response. 
  EP1 defi  ciency does not affect migration and maturation 
of DCs during the CHS 
  The aforementioned results showing that the EP1 defi  ciency 
impairs generation of Th1 cells in draining LNs indicates that 
the EP1 signaling regulates functions for Th1 diff  erentiation of 
either DCs, naive T cells, or both. DCs functioning in the 
  Figure 3.     EP1    −  /  −    mice showed reduced Th1 response in the elicita-
tion phase of CHS. Cells were collected from LNs 5 d after the sensitiza-
tion (A) or challenge (B and C) with DNFB, and the cell number was 
counted by fl  ow cytometry. (A) Number of T-bet  +   cells from inguinal and 
axillary LNs during sensitization phase. Sensitization increased the number 
of T-bet  +   cells in WT and EP1   − / −    mice, but the increase was attenuated in 
EP1   − / −    mice  (unpaired  Student ’ s   t   test;   n   = 5 mice per group). (B) Num-
ber of cells in cervical LNs during elicitation phase. EP1   − / −    mice  showed 
decreased cell number in cervical LNs 24 h after challenge (unpaired Stu-
dent ’ s   t   test;   n   = 5 mice per group). (C) Analysis of lymphocyte subsets in 
regional LNs after challenge. Cells were collected from cervical LNs 24 h 
after the challenge, and the numbers of CD4  + ,  CD8 +  , and B220  +   cells con-
taining IFN-      were analyzed by fl  ow cytometry (unpaired Student  ’  s   t   test; 
  n   = 5 mice per group). Data are representative of at least three experi-
ments with similar results. Data are presented as the mean   ±   the SEM.     JEM VOL. 204, November 26, 2007 
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  In contrast to these results on Th1 and Tc1 cells, the addition 
of DI-004 decreased the number of IL-4  –  producing cells in a 
dose-dependent manner both from naive CD4  +   cells and CD8  +   
T cells under the Th2-skewing condition (  Fig. 5, E and F  ). This 
inhibitory eff  ect of DI-004 on Th2 diff  erentiation was again 
impaired in naive T cells isolated from EP1    −  /  −    mice. These 
results, thus, suggest that EP1 activation facilitates Th1 diff  er-
entiation, but suppresses Th2 diff  erentiation, at least under 
these in vitro conditions. To clarify the impact of diff  erent 
PGE  2   signaling on T cell diff  erentiation, we next exposed 
CD4  +   T cells to either an EP2 agonist or an EP4 agonist under 
the aforementioned Th1-skewing conditions. Both butaprost, 
which is an EP2 agonist, and AE-1-329, which is an EP4 ago-
nist, suppressed diff  erentiation to Th1 in a concentration-
dependent manner, although AE-1-329 showed a stronger 
eff  ect than butaprost (  Fig. 5 C  ). Consistent with previous 
reports (  9  –  11  ), the addition of PGE  2   itself to naive CD4  + 
T cells in this system suppressed Th1 diff  erentiation like EP2 
or EP4 agonist (Fig. S4, available at http://www.jem.org/cgi/
content/full/jem.20070773/DC1). Finally, to clarify the role 
of EP receptor subtypes in T cell diff  erentiation, we examined 
expression of EP subtypes in Th1- and Th2-diff  erentiated 
T cells (  Fig. 5 G  ). We found that EP1 is up-regulated both in 
Th1 and Th2 cells, whereas EP2 and EP4 are down-regulated, 
between the two genotypes in the morphology and the number 
of LCs in the skin in steady state, reduction of epidermal LCs 
  after the antigen application and an increase of CD11c  +  MHC 
class II  +   cells in the draining LNs 24 h after the application 
(Fig. S3, A  –  C, available at http://www.jem.org/cgi/content/
full/jem.20070773/DC1). Antigen-induced expression of the 
costimulatory molecules CD80 and CD86 on DCs was un-
aff  ected in EP1    −  /  −    mice (Fig. S3 D). To test whether EP1 
regulates production of IL-12 by DCs, we examined the number 
of IL-12  +  CD11c  +   cells in the regional LNs. EP1    −  /  −    mice 
exhibited a similar time-dependent increase in the number of 
IL-12  +  CD11c  +   cells in LNs compared with that in WT mice 
after the DNFB application (Fig. S3 E). Furthermore, the ad-
dition of the EP1 agonist DI-004 (  32  ) to WT DCs did not 
enhance the anti-CD40  –  stimulated production of IL-12 in vitro 
(Fig. S3 F). These results suggest that EP1 signaling in DCs, if 
present, does not play a substantial role in inducing Th1 diff  er-
entiation in our model of CHS. 
  EP1 activation facilitates Th1 differentiation, but 
suppresses Th2 differentiation in vitro 
  The aforementioned results, when taken together, strongly 
suggest the importance of EP1 signaling in naive T cells in 
Th1 and Tc1 cell generation. Therefore, we examined the 
level of EP1 expression in naive T cells by quantitative PCR 
analysis. This analysis revealed that EP1 is expressed to a level 
comparable to EP2 and EP4 in both CD4  +   and CD8  +   T cells 
(  Fig. 5 A  ).   EP1 expression on naive T cells was confi  rmed by 
fl  ow cytometry using polyclonal antibody for EP1 (  Fig. 5 B  ). 
Given the well-known actions of EP2 and EP4 on T cells, it is 
quite likely that EP1 also mediates physiological response in 
T cells. To dissect an EP1 action in Th1 diff  erentiation, we 
exploited the in vitro culture system for Th diff  erentiation, 
and exposed purifi  ed naive CD4  +   T cells to either the Th1- or 
the Th2-skewing conditions (  33  ) in the presence or absence of 
an EP1 agonist. We then assessed the extent of Th1/Th2 dif-
ferentiation by FACS analyses with the intracellular IFN-      
and IL-4 as markers of Th1 and Th2 cells, respectively. Under 
the Th1-skewing condition, in which naive CD4  +   T cells dif-
ferentiated selectively to IFN-       –  producing T cells, activation 
of EP1 by the EP1 agonist DI-004 signifi  cantly increased the 
number of IFN-       –  producing cells in naive CD4  +   T cells iso-
lated from WT mice in a dose-dependent manner (  Fig. 5 C  ). 
This eff  ect of DI-004 on Th1 diff  erentiation was impaired in 
naive CD4  +   T cells from EP1    −  /  −    mice, indicating that the 
facilitation by DI-004 was mediated via EP1. Similar to Th1 and 
Th2 cells, the two subsets of CD8  +   cytotoxic T cells, Tc1 and 
Tc2 cells, expressed Th1 cytokines such as IFN-      and Th2 
  cytokines such as IL-4, respectively. It is also known that the 
Th1- and Th2-skewing conditions can diff  erentiate naive 
CD8  +   T cells into Tc1 and Tc2 cells. Therefore, we examined 
whether the EP1 stimulation also facilitates Tc1 diff  erentiation. 
The addition of DI-004, indeed, facilitated Tc1 diff  erentiation 
from naive CD8  +   T cells under a Th1-skewing condition, 
which was suppressed in CD8  +   T cells from EP1    −  /  −    mice 
(  Fig. 5 D  ). 
  Figure 4.     CHS response after adoptive transfer. (A) Attenuated CHS 
response in WT recipients adoptively transferred with sensitized EP1   − / −    T 
cells. T cells were isolated and pooled from LNs of DNFB-sensitized WT (   ) 
or EP1   − / −    (   ) donors and adoptively transferred into naive WT recipients 
(repeated ANOVA;   n   = 5 per group). (B) Intact CHS response in EP1   − / −    recipi-
ents adoptively transferred with sensitized WT T cells. T cells from sensitized 
WT donors were transferred into naive WT (    ) or EP1   − / −    (  )  recipients 
(repeated ANOVA;   n   = 5 per group). Data are representative of three experi-
ments with similar results. Data are presented as the mean   ±   the SEM.    2870 FACILITATION OF TH1 RESPONSE BY PGE RECEPTOR EP1 | Nagamachi et al.
Th1 diff  erentiation is achieved, for example, by prolonged in-
cubation with IL-12 (Fig. S5, available at http://www.jem.org/
cgi/content/full/jem.20070773/DC1). These results suggest 
that the EP1-dependent mechanism functions as a booster of 
suboptimal conditions. To test such a booster function of EP1 
in vivo, we performed the immunization with a high dose (1%) 
of DNFB, and examined the DNFB-elicited ear infl  ammation. 
We found that under these conditions, EP1    −  /  −    mice exhibited a 
suggesting a possibility that EP1 works dominantly during T 
cell diff  erentiation to Th1 and Th2. 
  It should be noted that the condition of the in vitro diff  er-
entiation in   Fig. 5   was set by choosing the concentrations of 
cytokines and the time points of experiment to the condition 
in which initial rise of Th1 diff  erentiation can be observed. 
The eff  ects of EP1 stimulation were seen only in this condi-
tion and were masked in the condition in which maximum 
  Figure 5.     Effect of EP1 stimulation on T cell differentiation to Th1 and Th2 subsets in vitro. (A) Quantitative PCR analysis on expression for 
mRNAs of four EP subtypes in CD4  +   and  CD8 +   T cells. Arbitrary expression units are shown. (B) Flow cytometric analysis of EP1 expression on naive CD4  +  
T cells. Naive CD4  +   T cells from WT mice were stained for EP1 with rabbit polyclonal anti-EP1 antibody and Alexa Fluor 488  –  labeled anti  –  rabbit IgG in the 
presence (dotted line) or absence (solid line) of antigenic peptide and subjected to fl  ow cytometry. A control experiment using the second antibody alone 
is shown in gray. (C) Enhancement by EP1 stimulation and suppression by EP2 and EP4 stimulation of Th1 differentiation of naive CD4  +   T cells. Naive 
CD4  +   T cells from WT mice were cultured under the Th1 skewing condition with indicated concentrations of an EP1 agonist (DI-004, white columns), an 
EP2 agonist (butaprost, gray columns), and an EP4 agonist (AE-1-329, striped columns) or naive CD4  +   T cells from EP1   − / −    mice were cultured in the same 
conditions with an EP1 agonist (black columns). (D) Naive CD8  +   T cells from WT (white columns) and EP1   − / −    mice (black columns) were cultured under 
the Tc1-skewing condition with or without DI-004. (E) Naive CD4  +   T cells from WT (white columns) and EP1   − / −    mice (black columns) were cultured 
under the Th2-skewing condition with or without DI-004. (F) Naive CD8  +   T cells from WT (white columns) and EP1   − / −    mice (black columns) were cultured 
under the Tc2-skewing condition with or without DI-004. *, P   <   0.05 versus respective control values without each agonist (ANOVA with Tukey-Kramer 
multiple-comparison test;   n   = 5 per group). Data are representative of at least three separate experiments with similar results. (G) Quantitative PCR analysis 
on expression for mRNAs of four EP subtypes in Th1- and Th2-differentiated T cells. Th1 and Th2 cells differentiated from naive T cells were isolated as 
described in the Materials and methods and subjected to quantitative PCR analysis. Data are presented as the mean   ±   the SEM.    JEM VOL. 204, November 26, 2007 
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concentrations of LPS for 24 h. Both WT and mPGES1    −  /  −    
DCs secreted a small amount of PGE  2   without stimulation, 
and whereas stimulation with LPS induced the production 
of PGE  2   in a dose-dependent manner in WT cells, no LPS-
induced augmentation of PGE  2   production was observed 
in mPGES-1    −  /  −    DCs (Fig. S7 B), suggesting that mPGES-1 is 
responsible for PGE  2   production by activated DCs. Based on 
these fi  ndings, we wondered whether activated DCs express-
ing mPGES-1 migrate to draining LNs after immunization. 
Indeed, staining of dissociated LN cells for mPGES-1 and im-
mune cell markers revealed that CD11c  +   DCs, but not by 
Thy1.2  +   T cells or B220  +   B cells, expressed mPGES-1 in 
draining LNs (  Fig. 6 A  ), and the fl  ow cytometry showed that 
the number of mPGES-1  +  CD11c  +   cells signifi  cantly increased 
in draining LNs after DNFB sensitization (  Fig. 6 B  ).   These re-
sults indicate that the DNFB immunization induces mPGES-1 
expression in CD11c  +   DCs, which then reach the draining 
LNs and actively produce PGE  2   there during antigen-induced 
T cell proliferation and diff  erentiation. PGE  2   produced in this 
manner in the LNs can act on T cells in a paracrine manner. 
      DISCUSSION   
    Although it has long been known that PGE  2   exerts immuno-
suppression in vitro, little is known how PGE  2   is involved in 
immune response in vivo. We used EP1    −  /  −    mice and ad-
dressed this issue. Our results suggest that the PGE  2    –  EP1 
pathway in T cells facilitates T cell diff  erentiation to the Th1 
subset and Th1-mediated immune response in vivo. This sug-
gestion is supported by several lines of evidence. First, EP1    −  /  −    
similar extent of ear swelling compared with WT mice (Fig. S6), 
suggesting that the requirement of the PGE  2    –  EP1 pathway was 
overcome by strong immunization stimulus. 
  PGE  2   production by CD11c  +   DCs in draining LNs after 
DNFB stimulation 
  We have thus demonstrated the critical role of the PGE  2    –  EP1 
signaling in Th1 diff  erentiation during CHS. To further char-
acterize the mechanism responsible for these observations, we 
tried to identify a cell type that produces PGE  2   in this process. 
It was reported that APCs, including DCs, can produce a large 
amount of PGE  2   in vitro (  7  ). Consistently, WT CD11c  +   DCs 
purifi  ed from the spleen produced PGE  2   under the unstimu-
lated conditions, and this production was further augmented 
by LPS stimulation, whereas CD4  +   or CD8  +   T cells released 
only a negligible amount of PGE  2  , even upon anti-CD3 stim-
ulation (Fig. S7 A, available at http://www.jem.org/cgi/
content/full/jem.20070773/DC1). To characterize the PGE  2   
production by DCs, we examined the identity of PGE syn-
thase (PGES) involved in this process. PGE  2   is produced by 
the sequential catalysis of COX and PGES. Each of these en-
zymes has two molecular isoforms, constitutive COX-1 and 
inducible COX-2 and constitutive cytosolic PGES (cPGES) 
and inducible membrane-associated PGES-1 (mPGES-1), 
respectively (  34  ). In macrophages, proinfl  ammatory stimuli 
induce expression of COX-2 and mPGES-1 together, which 
then work in concert for PGE  2   production (  35  ). Therefore, 
we purified DCs from the spleen of mPGES-1  –  deficient 
(mPGES-1    −  /  −   ) mice (  36  ) and cultured them with various 
  Figure 6.     CD11c  +   DCs expressing mPGES-1 increase in number in draining LNs after DNFB application. (A) Identifi  cation of LN cells expressing 
mPGES-1. Cells were collected from the draining LNs on day 1 after DNFB application, subjected to cytospin, and stained for mPGES-1, CD11c, Thy1.2, and 
B220. Bar, 10      m. (B) Increased number of mPGES-1  + CD11c +   cells in draining LNs during sensitization phase of CHS. Cells were collected from inguinal 
and axillary LNs 24 h after the sensitization and analyzed by fl  ow cytometry (unpaired Student  ’  s   t   test;   n   = 5 per group). Data are representative of at 
least three experiments with similar results. Data are presented as the mean   ±   the SEM.     2872 FACILITATION OF TH1 RESPONSE BY PGE RECEPTOR EP1 | Nagamachi et al.
stimuli. For example, expression of EP2 and EP4 in macro-
phages is up-regulated by bacterial endotoxin (  39  ). Expression 
of the thromboxane receptor in T cells is down-regulated 
during T cell activation (  22  ). In this study, we found that EP1 
is up-regulated, whereas EP2 and EP4 are down-regulated, in 
diff  erentiated Th1 and Th2 cells (  Fig. 5 G  ). Furthermore, a 
previous study reported that PGE  2   acts on EP3 and promotes 
production of IFN-      from established Th1 cells and Th1 
clones (  40  ). These observations indicate that the EP expression 
profi  le may vary depending on the pathogens and antigens 
they are exposed to, innate immune responses, and stage of T 
cell diff  erentiation, and they determine the fi  nal outcome of 
T cells in response to PGE  2  . 
  If so, then where in the body is PGE  2   produced, and does 
it exert its action in the course of sensitization? Because PG 
acts only in the vicinity of its synthesis, PGE  2   acting on naive 
T cells should be produced in situ in draining LNs close to 
the T cells. In this study, we found that CD11c  +   cells produce 
a large amount of PGE  2   upon infl  ammatory stimuli in a 
mPGES-1  –  dependent manner, and that CD11c  +  mPGES-1  +   
cells in the draining LNs increased in number after the DNFB 
application to the skin. Given that mPGES-1 and COX-2 are 
induced simultaneously and work in concert to produce PGE  2   
in macrophages (  41  ), these fi  ndings indicate that mPGES-1 is 
induced in DCs upon the DNFB application, and that acti-
vated DCs expressing mPGES-1 migrate to draining LNs, 
where they produce PGE  2   that acts on EP1 on naive T cells to 
facilitate Th1 diff  erentiation. 
  In conclusion, we found that the PGE  2    –  EP1 pathway is 
critically involved in Th1-mediated immune response in vivo 
by shifting the Th1/Th2 balance to Th1 dominance. Given 
that the EP1 antagonist mimics the EP1    −  /  −    phenotype and that 
the EP1 agonist can facilitate Th1 diff  erentiation in vitro, this 
signaling may be a step at which the Th1/Th2 balance can 
be manipulated pharmacologically. 
      MATERIALS AND METHODS   
    Mice.       EP1    −  /  −    mice (  42  ), backcrossed   >  10 times onto C57BL/6CrSlc (Japan 
SLC), and WT control littermates were bred in specifi  c pathogen  –  free facil-
ities at Kyoto University. mPGES-1        /           mice were provided by S. Uematsu 
and S. Akira (Osaka University, Osaka, Japan) (  36  ). All experimental proce-
dures were approved by the institutional animal care and use committee of 
Kyoto University Faculty of Medicine (Kyoto, Japan). 
    Reagents and antibodies.       DNFB and DNBS were purchased from Sigma-
Aldrich. An EP1 antagonist (ONO-8713), an EP1 agonist (ONO-DI-004), an 
EP2 agonist (butaprost), and an EP4 agonist (ONO-AE-1-329) were provided 
by Ono Pharmaceutical Co. FITC- or PE-conjugated RM4-5 (anti-CD4), 
53  –  6.7 (anti-CD8), RA3-6B2 (anti-B220), HL3 (anti-CD11c), 16-10A1 
(anti-CD80), GL1 (anti-CD86), M5/114.15.2 (anti-MHC class II), or IM7 
(anti-CD44) mAbs were purchased from BD PharMingen. FITC- or PE-con-
jugated 11B11 (anti-IL-4), XMG1.2 (anti-IFN-     ), and N418 (anti-CD11c) 
mAbs were purchased from eBioscience. FITC-conjugated 4B10 (anti  –  T-bet) 
mAb was purchased from Santa Cruz Biotechnology. Rabbit polyclonal anti  –
  mPGES-1 and anti-EP1 antibodies were purchased from Cayman Chemicals. 
    CHS protocol.       On day 0, female mice were sensitized with 25      l of 0.5 or 
1% (wt/vol) DNFB in acetone/olive oil (4/1, vol/vol) on shaved abdominal 
skin. On day 5, ears were challenged by application of 20      l of 0.3% DNFB 
mice exhibited a signifi  cant decrease in DNFB-induced, Th1-
mediated CHS response compared with that in WT mice. 
This phenotype was recapitulated by administration of the EP1-
specifi  c antagonist during the sensitization period, suggesting 
the involvement of EP1 in the immunization step. On the other 
hand, production of IgE to OVA was not impaired in EP1    −  /  −    
mice. Thus, impairment in EP1    −  /  −    mice was restricted to 
the Th1 response. Second, analysis of the LNs in the sensiti-
zation period revealed that, whereas cutaneous DCs mi-
grated to the regional LNs and T cells proliferated in EP1    −  /  −    
mice as seen in WT mice, diff  erentiation of T cells to Th1 
cells was signifi  cantly impaired. Furthermore, adoptive trans-
fer experiments demonstrated the critical role of T cells in 
mediating the EP1 action in CHS. Third, incubation of naive 
T cells with the EP1-selective agonist in vitro enhanced their 
diff  erentiation to either Th1 or Tc1 subset, and suppressed 
diff  erentiation to either Th2 or Tc2 subset. This suppression 
of Th2/Tc2 subset may be caused by enhancement of Th1/
Tc1 action that potentially antagonizes Th2/Tc2 diff  erentia-
tion. Consistent with the latter fi  nding, EP1 defi  ciency tends 
to enhance Th2 response in vivo. Notably, the EP1 agonist 
failed to induce Th1 diff  erentiation without IL-12, indicating 
that the EP1 stimulation itself cannot induce Th1 diff  erentia-
tion, but enhances the action of IL-12 (Fig. S5). Furthermore, 
the fi  ndings that the action of the PGE  2    –  EP1 signaling that 
was seen in the submaximal condition (Fig. S5 and S6) functions 
signifi  cantly in vivo suggests the importance of immunomod-
ulatory substances acting in concert with cytokine signaling in 
determining the extent of physiological immune response. 
Thus, our study has revealed that PGE  2   acts through EP1 for 
amplifi  cation of Th1 diff  erentiation. 
  The PGE  2   action we found here is opposite to the well-
known PGE  2  -induced suppression of Th1 cells found in pre-
vious studies (  9, 37, 38  ). Interestingly, the latter action is 
mediated by EP2 and EP4 receptors that couple to an increase 
in the cAMP level, whereas stimulation of EP1 induces a rise in 
intracellular concentration of free calcium ion (  6  ), which may 
contribute to up-regulation of T-bet (  27  ). The impact of such 
diff  erential action of PGE  2   mediated by diff  erent receptors 
is illustrated in   Fig. 5 C  , which shows that the addition of the 
EP1 agonist or the EP2 and EP4 agonists to conditions that 
are otherwise the same induces signifi  cant enhancement or sig-
nifi  cant suppression of Th1 diff  erentiation, respectively. These 
results indicate that PGE  2   can exhibit diff  erent actions in the 
immune system dependent on the receptor subtypes diff  ering 
in signal transduction pathways. If so, what determines the fi  nal 
outcome of PGE  2   action in Th cell diff  erentiation? We observed 
here that EP1    −  /  −    mice showed decreased CHS response 
to DNFB because of impaired diff  erentiation to Th1 cells. 
On the other hand, our previous study showed that in the 
absence of EP4, T cells proliferates in the lamina propria of the 
intestine of mice subjected to dextran sodium sulfate-induced 
colitis (  18  ). Such diff  erence may refl  ect the expression profi  le 
of the prostanoid receptors of T cells in each situation. We 
now know that expression of prostanoid receptors are dy-
namically modulated by various physiological and pathological JEM VOL. 204, November 26, 2007 
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consistently   >  90%. For in vitro diff  erentiation assays (  33  ), CD4  +   or CD8  +   
T cells were stimulated for 2 d with 10   μ  g/ml of plate-bound anti-CD3 and 
in the presence of 10 ng/ml IL-12 and 10   μ  g/ml anti  –  IL-4, and 2,500 U/ml 
IL-2 for Th1 diff  erentiation, or in the presence of 10 ng/ml IL-4, 10   μ  g/ml 
anti-IFN-     , and 2,500 U/ml IL-2 for Th2 diff  erentiation with or without 
DI-004, butaprost, AE-1-329, or PGE  2   (1      M or 10      M). 40 or 48 h after 
primary stimulation, cells were washed and further cultured under the Th1 or 
Th2 condition without anti-CD3. 18 h after incubation, cells were stimu-
lated by PMA and ionomycin for 6 h, and cytokine production was deter-
mined by intracellular cytokine staining, as previously described (  22  ). For 
detection of EP receptors on Th1 and Th2 cells, after primary stimulation for 
48 h, cells were washed and further cultured under the Th1 or Th2 condition 
without anti-CD3. 6 d later, IFN-       –  producing Th1 cells and IL-4  –  producing 
Th2 cells were isolated by using the cytokine secretion assays kits (Miltenyi 
Biotech) and subjected to quantitative PCR. 
    Quantitative PCR analysis.       Total RNA from purifi  ed cells was isolated 
with the RNeasy kit using on-column DNase I digestion (QIAGEN). 
Quantitative RT-PCR with the Light Cycler real-time PCR apparatus was 
performed according to the instructions of the manufacturer (Roche) by 
monitoring the synthesis of double-stranded DNA during the various PCR 
cycles using SYBR Green I (Roche). For each sample, triplicate test reac-
tions and a control reaction lacking reverse transcriptase were analyzed for 
expression of the gene of interest, and results were normalized to those of the 
  “  housekeeping  ”   GAPDH mRNA. Arbitrary expression units were calcu-
lated by division of expression of the gene of interest by GAPDH mRNA 
expression and multiplication of the result by 1,000. 
    Statistical analysis.       Data are presented as the mean   ±   the SEM. Unless other-
wise indicated, all P values were calculated with the two-tailed Student  ’  s   t   test. 
    Online supplemental material.       Fig. S1 shows analysis of the IFN-       –  pro-
ducing CD8  +   cell population in cervical LNs after challenge. Fig. S2 shows 
serum IgE levels after OVA immunization in EP1    −  /  −    mice. Fig. S3 includes 
supporting data for intact migration and maturation of DCs in EP1    −  /  −    mice. 
Fig. S4 shows the eff  ect of PGE  2   on T cell diff  erentiation to Th1. Fig. S5 
shows enhancing eff  ect of EP1 agonist on IL-12  –  induced T cell diff  erentiation 
to Th1. Fig. S6 shows CHS response of EP1    −  /  −    mice and WT mice to sensiti-
zation with a higher dose of DNFB. Fig. S7 shows mPGES-1  –  dependent 
PGE  2   production by CD11c  +   cells. The online version of this article is avail-
able at http://www.jem.org/cgi/content/full/jem.20070773/DC1. 
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